fascinating join to company great in time need. at been in It's and patients Invivyd Jeremy. Thanks, for a the
X. Slide to Turning
reminder, Phase who for have moderate-to-severe COVID-XX immune EUA As that ongoing clinical our and a Canopy for in trial certain includes compromise PrEP X is adults based III adolescents the cohorts. upon
a subjects, we First, immunocompromised Cohort have A. so-called cohort in open-label the single-arm
from safety a with infection endpoints, SARS-CoV-X is double-blind there cohort B. event so-called Second, people risk exploratory the meetings of clinical in at Cohort regular face-to-face randomized
events COVID on ongoing information exploratory collected an have on We both arms in basis.
of the the events a arm renders A, placebo more cohort Although obviously, opaque. bit interpretation in lack of the a
Moving to Slide X.
then we antibody FDA, to to in VYDXXX, titers PK half-life now reminder, immunobridging to allowed with very a the PEMGARDA. ordinary and As high with the titers order dosed endpoint of decay the subject meet to agreed to
can produce a major then which boost imagine expect fall another rate. You titers, that a to redose will at we similar well will
phase which how As forward. to calculation dose we titers, very lower dose, every prior us forward in a calibrate accrue second high seeing look time to trough to give we with day involves information period XX help Perhaps events we us titers. our any a dose optimization then could levels, going may collect descent that that a after
Turning to Slide XX.
As a wave. reminder, CANOPY and began fall/winter the XXXX-XXXXX then into the trial going clinical JN.X we through
attack result, of a about X%. in rate As study robust X% saw we a our relatively to
the of COVID-XX, protection symptomatic Although may to with product endpoints COVID-XX powered profile about have the was not and note going consider unrelated protection in FDA's titers forward. our analysis were we levels and application, various review exploratory CANOPY of from and events of demonstrate that we CANOPY think symptomatic value associated as that exploratory be prospectively dose of designed EUA or to events
titers. previously Pemivibart day arm Cohort XX, one have infection approximately that high our with compared a double-blind placebo-controlled period through the sVNA XX, arm, very Placebo Through overlap in of risk We a in XXX% saw we XX%. to we yielding protection that X reduction relative of in day B, breakthrough the disclosed observed cohort,
add we second resolution interval the post these awaiting of forward on data A have slide, previous to are XX, later will additional XX-day are sharing that thinking. while upcoming of day we our and Cohort that additional We highlighted the cases blinded occurred summer. As this Cohort look the in analysis dose to aware COVID-XX B
Slide XX. to Turning
our PEMGARDA moderate announced EUA people. recently to we request for an symptomatic in certain Importantly, intention submit mild to for immunocompromised treatment the COVID-XX of
bridging As sets data between welcome and we the anticipated release, initiate monotherapy will design virology reminder from the alignment a CANOPY and already compact clinical submission complement and request, trial on a EUA submission to existing our reassuring and pharmacokinetic described leverage of serial focused anticipated data. intellectual view to Invivyd in our as generating our safety, In to clinical parallel confirmatory press overall logical and EUA U.S. of we the FDA.
The trials. a the this treatment and STAMP plan clinical paradigm
than follow-up which of moving second and treatment forward. and certain immunocompromised shorter-term with Importantly, case people substantiate symptomatic a may PEMGARDA molecules mild-to-moderate is possibly innovation use endpoints COVID-XX for PrEP, rapid
case Turning current because and driver disproportionately is to vaccination, impacted and death in people Slide even are molecule XX. by This with additional despite U.S. outcomes use a COVID-XX important severe treatment options. immuno-compromised remain major small hospitalization of the ongoing
appropriate to PEMGARDA Moving certain option armamentarium addition immune alternative to COVID-XX and with options If therapeutic moderate not Slide welcome XX. to the a when valuable for treatment a authorized, severe were people compromise potential on intravenous clinically authorized days. are could consecutive or and burdensome are setting antibody accessible. others At some is interactions existing present, no and treatment infusions requiring in COVID-XX there repeat hospital of a by mainly among drug-drug options, deployed complicated be
XX. Turning Slide to
ebbs option pandemic, X As the heavily flows remain Nonetheless, seen since year beginning COVID treatment of therapies, viral with we and in the presence. treatments utilization overall COVID of have utilized.
and as with our that pleased the Discovery moving urgency provides with efficient important Robbie PrEP.
I deliver immunobridging our with are call discuss COVID-XX rapid believe us treatment analytics to We a turn now option, to am more and efforts to complementing considerable to an pathway we Technologies.
